What does EBS PHARMA do?

EBS PHARMA is a food producer in Beringen. Private Limited, started on 29 January 2018, 1 establishment.

What is the address of EBS PHARMA?

The registered office of EBS PHARMA is located at Kruisbaan 130, 3580 Beringen.

Is EBS PHARMA still active?

Yes. According to the CBE (16 September 2026) EBS PHARMA is active, legal situation “Normale toestand”, started on 29 January 2018.

Is EBS PHARMA registered on Peppol?

Yes, EBS PHARMA is registered on the Peppol network with ID 0208:0688975657.

What is the enterprise number of EBS PHARMA?

The enterprise number of EBS PHARMA is BE0688975657.

When was EBS PHARMA founded?

EBS PHARMA was founded on 29 January 2018.

Who are the directors of EBS PHARMA?

According to the 2025 annual accounts, the directors of EBS PHARMA are: TRI-SANA BV, TRI-FORCE CONSULTING BV.

Is EBS PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 January 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did EBS PHARMA make in 2025?

EBS PHARMA posted a profit after taxes of € 22,677 in financial year 2025.

What is the revenue of EBS PHARMA?

As a small company, EBS PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 24,528.

EBS PHARMA (Private Limited) - Beringen - BE0688975657

Dossier EBS PHARMA, printed on 16 September 2026 from databakkes.be/en/0688975657/ebs-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

EBS PHARMA from Beringen, company number BE0688975657, closed financial year 2025 with a result of € 22,677 after tax. For that financial year EBS PHARMA recorded a gross margin of € 24,528 and equity of € 20,714. Compared with financial year 2024, the result moved from € 19,484 to € 22,677. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 15, 2026.

What it is worth Healthy

€ 20,714

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 22,677

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 54,530

▲ 11% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 23,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

Debts at end 2025

Bank debt

€ 25,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 1,966

▼ 72% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 27,916 Gross margin 2022: € 27,916 First fiscal year in the series	€ 28,467 Gross margin 2023: € 28,467 ▲ 2% vs 2022 (€ 27,916) Favourable step	€ 21,636 Gross margin 2024: € 21,636 ▼ 24% vs 2023 (€ 28,467) Unfavourable step	€ 24,528 Gross margin 2025: € 24,528 ▲ 13% vs 2024 (€ 21,636) Favourable step	▲ 13%
Profit after taxes	€ 23,302 Profit after taxes 2022: € 23,302 First fiscal year in the series	€ 26,526 Profit after taxes 2023: € 26,526 ▲ 14% vs 2022 (€ 23,302) Favourable step	€ 19,484 Profit after taxes 2024: € 19,484 ▼ 27% vs 2023 (€ 26,526) Unfavourable step	€ 22,677 Profit after taxes 2025: € 22,677 ▲ 16% vs 2024 (€ 19,484) Favourable step	▲ 16%
Equity	€ 20,526 Equity 2022: € 20,526 First fiscal year in the series	€ 21,053 Equity 2023: € 21,053 ▲ 3% vs 2022 (€ 20,526) Favourable step	€ 21,036 Equity 2024: € 21,036 Unchanged (€ 21,053) Unfavourable step	€ 20,714 Equity 2025: € 20,714 ▼ 2% vs 2024 (€ 21,036) Unfavourable step	▼ 2%
Total debts	€ 54,601 Total debts 2022: € 54,601 First fiscal year in the series	€ 53,830 Total debts 2023: € 53,830 ▼ 1% vs 2022 (€ 54,601) Favourable step	€ 55,219 Total debts 2024: € 55,219 ▲ 3% vs 2023 (€ 53,830) Unfavourable step	€ 53,601 Total debts 2025: € 53,601 ▼ 3% vs 2024 (€ 55,219) Favourable step	▼ 3%
Cash	€ 64,536 Cash 2022: € 64,536 First fiscal year in the series	€ 57,937 Cash 2023: € 57,937 ▼ 10% vs 2022 (€ 64,536) Unfavourable step	€ 48,995 Cash 2024: € 48,995 ▼ 15% vs 2023 (€ 57,937) Unfavourable step	€ 54,530 Cash 2025: € 54,530 ▲ 11% vs 2024 (€ 48,995) Favourable step	▲ 11%
Retained profit	€ 1,926 Retained profit 2022: € 1,926 First fiscal year in the series	€ 2,453 Retained profit 2023: € 2,453 ▲ 27% vs 2022 (€ 1,926) Favourable step	€ 2,436 Retained profit 2024: € 2,436 ▼ 1% vs 2023 (€ 2,453) Unfavourable step	€ 2,114 Retained profit 2025: € 2,114 ▼ 13% vs 2024 (€ 2,436) Unfavourable step	▼ 13%
Dividend	€ 23,000 Dividend 2022: € 23,000 First fiscal year in the series	€ 26,000 Dividend 2023: € 26,000 ▲ 13% vs 2022 (€ 23,000) Unchanged	€ 19,500 Dividend 2024: € 19,500 ▼ 25% vs 2023 (€ 26,000) Unchanged	€ 23,000 Dividend 2025: € 23,000 ▲ 18% vs 2024 (€ 19,500) Unchanged	▲ 18%
Bank debt	€ 25,000 Bank debt 2022: € 25,000 First fiscal year in the series	€ 25,000 Bank debt 2023: € 25,000 Unchanged (€ 25,000) Unchanged	€ 25,000 Bank debt 2024: € 25,000 Unchanged (€ 25,000) Unchanged	€ 25,000 Bank debt 2025: € 25,000 Unchanged (€ 25,000) Unchanged
Balance sheet total	€ 75,128 Balance sheet total 2022: € 75,128 First fiscal year in the series	€ 74,883 Balance sheet total 2023: € 74,883 Unchanged (€ 75,128) Unchanged	€ 76,255 Balance sheet total 2024: € 76,255 ▲ 2% vs 2023 (€ 74,883) Unchanged	€ 74,315 Balance sheet total 2025: € 74,315 ▼ 3% vs 2024 (€ 76,255) Unchanged	▼ 3%

Key figures of EBS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to EBS PHARMA?

What happened at EBS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 15, 2026 New annual accounts for financial year 2025: profit of € 22,677 (▲ 16% vs 2024). Source: NBB ↗
Jan 29, 2018 New establishment in Beringen. KBO
Jan 29, 2018 Start of the company according to the CBE. KBO
2018 TRI-SANA BV became a director. NBB
2018 TRI-FORCE CONSULTING BV became a director. NBB

In short

From € 23,302 profit in 2022 to € 22,677 profit in 2025.

Paid € 561 in corporate taxes since 2022.

Best year ever: 2023, with € 26,526 profit.

Paid out € 91,500 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at EBS PHARMA? We notify you, reason included.

Follow EBS PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit